Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer

Published:2021-01-01 Issue:1 Volume:24 Page:675-688
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Thurgar Elizabeth¹,Gouldson Mark¹,Matthijsse Suzette²,Amonkar Mayur³,Marinello Patricia³,Upadhyay Navneet³,Nwankwo Chizoba³,Aguiar-Ibáñez Raquel⁴

Affiliation:

1. BresMed Health Solutions Ltd, Sheffield, UK

2. BresMed Netherlands, Utrecht, The Netherlands

3. Merck & Co. Inc., Kenilworth, NJ, USA

4. Merck Canada Inc., Kirkland, Canada

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1917140

Reference49 articles.

1. National Cancer Institute. NCI – Endometrial Cancer. 2021 [cited 2021 Feb 2]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/endometrial-cancer

2. Epidemiology of endometrial cancer

3. Cancer.Net. Uterine Cancer: Statistics. 2020 [cited 2020 Feb 4]. Available from: https://www.cancer.net/cancer-types/uterine-cancer/statistics

4. Typical and atypical metastatic sites of recurrent endometrial carcinoma

5. Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer;Frontiers in Pharmacology;2024-06-20

2. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis;International Journal of Gynecologic Cancer;2024-06-20

3. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma;BMC Health Services Research;2024-05-29

4. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden;Journal of Medical Economics;2024-03-26

5. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost‐effectiveness analysis in the United States and in China;Journal of Obstetrics and Gynaecology Research;2024-03-14